COMMODORE CAPITAL LP Holdings

COMMODORE CAPITAL LP is an investment fund managing more than 621.89M US dollars. The largest holdings include Cogent Biosciences, Xenon Pharmaceuticals and Viridian Therapeutics. In Q3 2022 the fund bought assets of total value of 156.58M US dollars and sold assets of total value of 37.95M US dollars.

$621.88M

portfolio value

+17.28%

quarter

-11.77%

1 year

COMMODORE CAPITAL LP portfolio changes

Portfolio changes (number of shares)
Period	Buy	Sel
Q1 2021	71347000	94000
Q2 2021	64510000	13643000
Q3 2021	139335000	27100000
Q4 2021	146415000	48380000
Q1 2022	78525000	47202000
Q2 2022	85716000	52062000
Q3 2022	156577000	37950000

COMMODORE CAPITAL LP 13F holdings

Stock	Position type	Portfolio share	Portfolio value	Avg. open price	Current price	P/L	Last change
Biotechnology Cogent Biosciences, Inc. Portfolio share: 10.36% Portfolio value: 64.45M Avg. open price: $8.45 Current price: $12.5 P/L: +47.95% Sold -12.64% shares Q3 2022	share	10.36%	64.45M	$8.45	$12.5	+47.95%	Sold -12.64% shares Q3 2022
Biotechnology Xenon Pharmaceuticals Inc. Portfolio share: 9.26% Portfolio value: 57.57M Avg. open price: $22.07 Current price: $38.83 P/L: +75.90% Bought +32.62% shares Q2 2022	share	9.26%	57.57M	$22.07	$38.83	+75.90%	Bought +32.62% shares Q2 2022
Biotechnology Viridian Therapeutics, Inc. Portfolio share: 8.89% Portfolio value: 55.30M Avg. open price: $15.46 Current price: $26.84 P/L: +73.56% Bought +64.55% shares Q3 2022	share	8.89%	55.30M	$15.46	$26.84	+73.56%	Bought +64.55% shares Q3 2022
Biotechnology BELLUS Health Inc. Portfolio share: 8.71% Portfolio value: 54.15M Avg. open price: $8.33 Current price: $10.02 P/L: +20.35% Bought +14.48% shares Q3 2022	share	8.71%	54.15M	$8.33	$10.02	+20.35%	Bought +14.48% shares Q3 2022
Biotechnology Merus N.V. Portfolio share: 8.43% Portfolio value: 52.39M Avg. open price: $25.59 Current price: $14.2 P/L: -44.51% Bought +44.01% shares Q2 2022	share	8.43%	52.39M	$25.59	$14.2	-44.51%	Bought +44.01% shares Q2 2022
Biotechnology Cytokinetics, Incorporated Portfolio share: 6.96% Portfolio value: 43.29M Avg. open price: $35.92 Current price: $38.12 P/L: +6.13% Bought +4.56% shares Q2 2022	share	6.96%	43.29M	$35.92	$38.12	+6.13%	Bought +4.56% shares Q2 2022
Diagnostics & Research Aclaris Therapeutics, Inc. Portfolio share: 6.10% Portfolio value: 37.94M Avg. open price: $20.48 Current price: $15.66 P/L: -23.53% Bought +4.15% shares Q2 2022	share	6.10%	37.94M	$20.48	$15.66	-23.53%	Bought +4.15% shares Q2 2022
Biotechnology Akero Therapeutics, Inc. Portfolio share: 4.07% Portfolio value: 25.31M Avg. open price: N/A Current price: $44.04 P/L: N/A N/A Q3 2022	share	4.07%	25.31M	N/A	$44.04	N/A	N/A Q3 2022
Biotechnology Satsuma Pharmaceuticals, Inc. Portfolio share: 3.58% Portfolio value: 22.26M Avg. open price: $5.35 Current price: $0.89 P/L: -83.33% Bought +19.00% shares Q4 2021	share	3.58%	22.26M	$5.35	$0.89	-83.33%	Bought +19.00% shares Q4 2021
Biotechnology Tricida, Inc. Portfolio share: 3.33% Portfolio value: 20.70M Avg. open price: $8.89 Current price: $0.23 P/L: -97.44% Sold -2.62% shares Q3 2022	share	3.33%	20.70M	$8.89	$0.23	-97.44%	Sold -2.62% shares Q3 2022
Biotechnology CymaBay Therapeutics, Inc. Portfolio share: 3.23% Portfolio value: 20.08M Avg. open price: $4.58 Current price: $4.17 P/L: -8.97% Bought +5.88% shares Q1 2022	share	3.23%	20.08M	$4.58	$4.17	-8.97%	Bought +5.88% shares Q1 2022
Biotechnology Third Harmonic Bio, Inc. Portfolio share: 3.11% Portfolio value: 19.32M Avg. open price: N/A Current price: $22 P/L: N/A N/A Q3 2022	share	3.11%	19.32M	N/A	$22	N/A	N/A Q3 2022
Biotechnology Syndax Pharmaceuticals, Inc. Portfolio share: 2.85% Portfolio value: 17.73M Avg. open price: N/A Current price: $25.44 P/L: N/A N/A Q3 2022	share	2.85%	17.73M	N/A	$25.44	N/A	N/A Q3 2022
Biotechnology Celldex Therapeutics, Inc. Portfolio share: 2.44% Portfolio value: 15.14M Avg. open price: $33.34 Current price: $36.66 P/L: +9.95% Bought +123.39% shares Q2 2022	share	2.44%	15.14M	$33.34	$36.66	+9.95%	Bought +123.39% shares Q2 2022
Biotechnology Day One Biopharmaceuticals, Inc. Portfolio share: 2.38% Portfolio value: 14.81M Avg. open price: N/A Current price: $21.45 P/L: N/A N/A Q2 2022	share	2.38%	14.81M	N/A	$21.45	N/A	N/A Q2 2022
Biotechnology Arrowhead Pharmaceuticals, Inc. Portfolio share: 2.15% Portfolio value: 13.35M Avg. open price: $35.21 Current price: $31.87 P/L: -9.49% Bought +29.29% shares Q3 2022	share	2.15%	13.35M	$35.21	$31.87	-9.49%	Bought +29.29% shares Q3 2022
Biotechnology Kura Oncology, Inc. Portfolio share: 1.98% Portfolio value: 12.28M Avg. open price: $21.01 Current price: $15.82 P/L: -24.72% Sold -50.76% shares Q3 2022	share	1.98%	12.28M	$21.01	$15.82	-24.72%	Sold -50.76% shares Q3 2022
Biotechnology Acumen Pharmaceuticals, Inc. Portfolio share: 1.77% Portfolio value: 11.03M Avg. open price: N/A Current price: $5.6 P/L: N/A N/A Q3 2022	share	1.77%	11.03M	N/A	$5.6	N/A	N/A Q3 2022
Biotechnology Karyopharm Therapeutics Inc. Portfolio share: 1.70% Portfolio value: 10.56M Avg. open price: N/A Current price: $5.23 P/L: N/A Sold -45.65% shares Q2 2022	share	1.70%	10.56M	N/A	$5.23	N/A	Sold -45.65% shares Q2 2022
Biotechnology Allakos Inc. Portfolio share: 1.62% Portfolio value: 10.05M Avg. open price: N/A Current price: $8.14 P/L: N/A N/A Q3 2022	share	1.62%	10.05M	N/A	$8.14	N/A	N/A Q3 2022
Biotechnology Alpine Immune Sciences, Inc. Portfolio share: 1.53% Portfolio value: 9.54M Avg. open price: N/A Current price: $6.78 P/L: N/A N/A Q3 2022	share	1.53%	9.54M	N/A	$6.78	N/A	N/A Q3 2022
Biotechnology Celcuity Inc. Portfolio share: 1.49% Portfolio value: 9.24M Avg. open price: $24 Current price: $8.06 P/L: -66.42% Bought +5.68% shares Q3 2021	share	1.49%	9.24M	$24	$8.06	-66.42%	Bought +5.68% shares Q3 2021
Biotechnology Enanta Pharmaceuticals, Inc. Portfolio share: 0.86% Portfolio value: 5.36M Avg. open price: N/A Current price: $43.06 P/L: N/A N/A Q3 2022	share	0.86%	5.36M	N/A	$43.06	N/A	N/A Q3 2022
Biotechnology KalVista Pharmaceuticals, Inc. Portfolio share: 0.73% Portfolio value: 4.53M Avg. open price: $24.18 Current price: $5.17 P/L: -78.61% Bought +37.89% shares Q3 2021	share	0.73%	4.53M	$24.18	$5.17	-78.61%	Bought +37.89% shares Q3 2021
Biotechnology Rezolute, Inc. Portfolio share: 0.53% Portfolio value: 3.31M Avg. open price: N/A Current price: $1.71 P/L: N/A N/A Q2 2022	share	0.53%	3.31M	N/A	$1.71	N/A	N/A Q2 2022
Drug Manufacturers—Specialty & Generic Esperion Therapeutics, Inc. Portfolio share: 0.50% Portfolio value: 3.13M Avg. open price: N/A Current price: $7.49 P/L: N/A N/A Q3 2022	share	0.50%	3.13M	N/A	$7.49	N/A	N/A Q3 2022
Biotechnology Immunic, Inc. Portfolio share: 0.45% Portfolio value: 2.82M Avg. open price: N/A Current price: $1.34 P/L: N/A N/A Q1 2022	share	0.45%	2.82M	N/A	$1.34	N/A	N/A Q1 2022
Shell Companies BCLS Acquisition Corp. Portfolio share: 0.40% Portfolio value: 2.50M Avg. open price: N/A Current price: $10.04 P/L: N/A N/A Q4 2020	share	0.40%	2.50M	N/A	$10.04	N/A	N/A Q4 2020
Biotechnology Larimar Therapeutics, Inc. Portfolio share: 0.39% Portfolio value: 2.4M Avg. open price: N/A Current price: $3.15 P/L: N/A N/A Q3 2022	share	0.39%	2.4M	N/A	$3.15	N/A	N/A Q3 2022
Biotechnology Terns Pharmaceuticals, Inc. Portfolio share: 0.20% Portfolio value: 1.21M Avg. open price: N/A Current price: $6.09 P/L: N/A N/A Q3 2022	share	0.20%	1.21M	N/A	$6.09	N/A	N/A Q3 2022
Biotechnology IVERIC bio, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $9.57 Current price: $21.89 P/L: +128.85% Sold -100.00% shares Q3 2022	share	0.00%	0	$9.57	$21.89	+128.85%	Sold -100.00% shares Q3 2022
Biotechnology VistaGen Therapeutics, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $2.23 Current price: $0.12 P/L: -94.41% Sold -100.00% shares Q3 2022	share	0.00%	0	$2.23	$0.12	-94.41%	Sold -100.00% shares Q3 2022
Biotechnology Inventiva S.A. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $14.5 Current price: $4.45 P/L: -69.31% Sold -100.00% shares Q3 2022	share	0.00%	0	$14.5	$4.45	-69.31%	Sold -100.00% shares Q3 2022
Biotechnology Tenaya Therapeutics, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $2.42 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$2.42	N/A	Sold -100.00% shares Q3 2022

Showing TOP 34 COMMODORE CAPITAL LP's 13F holdings.

Frequently Asked Questions (FAQ)

What is the biggest position of COMMODORE CAPITAL LP?

The biggest position of the COMMODORE CAPITAL LP is Cogent Biosciences, Inc. (COGT) with 10.36% portfolio share worth of 64.45M US dollars.

Top 5 COMMODORE CAPITAL LP's holdings represent 45.65% of the portfolio:

Cogent Biosciences, Inc. (COGT) – 10.36%
Xenon Pharmaceuticals Inc. (XENE) – 9.26%
Viridian Therapeutics, Inc. (VRDN) – 8.89%
BELLUS Health Inc. (BLU) – 8.71%
Merus N.V. (MRUS) – 8.43%

Who is the portfolio manager of COMMODORE CAPITAL LP?

The portfolio manager of the COMMODORE CAPITAL LP is .

What is the total asset value of the COMMODORE CAPITAL LP portfolio?

COMMODORE CAPITAL LP total asset value (portfolio value) is 621.89M US dollars.

Who is ?

is the portfolio manager of the COMMODORE CAPITAL LP.

What is (COMMODORE CAPITAL LP) fund performance?

COMMODORE CAPITAL LP's quarterly performance is +17.28%, annualy -11.77%.

What is the COMMODORE CAPITAL LP CIK?

COMMODORE CAPITAL LP's Central Index Key is 0001831942 .